INQOVI (decitabine/cedazuridine) Patient Assistance Program
Don’t let the high cost of brand specialty oral MDS therapy disrupt your treatment. We help eligible patients access Inqovi (decitabine/cedazuridine) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Inqovi (decitabine and cedazuridine) is FDA-approved for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is the first FDA-approved oral hypomethylating agent (HMA) — combining oral decitabine with cedazuridine (a cytidine deaminase inhibitor) that prevents decitabine from being metabolized in the gut, allowing effective oral bioavailability.
- Without assistance, Inqovi costs commonly run approximately $20,000–$24,000 per 5-day cycle (one cycle every 28 days).
- Through AffordMyPrescriptions, qualifying patients can access Inqovi for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Inqovi in the U.S. as of 2026. Other MDS hypomethylating agents include IV/SC decitabine (Dacogen, generic available — much cheaper but requires infusions or injections) and IV/SC azacitidine (Vidaza, generic available). Onureg (oral azacitidine) is a separate oral HMA for AML maintenance. For higher-risk MDS, venetoclax + HMA combinations are increasingly used.
What Is Inqovi Prescription Assistance Program?
The Inqovi Prescription Assistance Program is a manufacturer-sponsored initiative that provides Inqovi at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for MDS and CMML patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, hematology/oncology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Inqovi costs roughly $20,000–$24,000 per 5-day cycle. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$23,000 | Save substantially |
| CVS Pharmacy | ~$24,000 | Save substantially |
| Walmart | ~$20,500 | Save substantially |
| Costco | ~$20,200 | Save substantially |
Specialty Pharmacy | ~$21,500 | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Inqovi Prescription Program?
The Patient Assistance Program is free to apply for and provides Inqovi at no medication cost if approved. Our $69.95/month service covers full advocacy. Generic IV decitabine and IV azacitidine are dramatically cheaper but require infusions — we’ll help your oncologist determine the best path balancing cost and convenience.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Inqovi:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $20,000–$24,000/cycle per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Inqovi assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Inqovi Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Inqovi:
Inqovi is the first FDA-approved oral hypomethylating agent (HMA) for MDS and CMML. It combines oral decitabine with cedazuridine — a cytidine deaminase inhibitor that prevents decitabine from being broken down in the GI tract and liver, allowing oral bioavailability roughly equivalent to IV decitabine. This enables MDS/CMML therapy without infusions.
How Inqovi Works:
Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) involve abnormal methylation of tumor suppressor genes. Inqovi works because decitabine reduces DNA methylation by depleting the DNMT1 enzyme, which reactivates silenced tumor suppressor genes and differentiation pathways. While oral decitabine alone is normally broken down rapidly by cytidine deaminase in the gut and liver, the addition of cedazuridine blocks this enzyme. This protection allows oral dosing to achieve drug exposures comparable to intravenous infusions.
Form and use:
Inqovi is administered as one tablet containing 35 mg decitabine and 100 mg cedazuridine once daily for 5 consecutive days of a 28-day cycle. It must be taken on an empty stomach, specifically at least 2 hours before and 2 hours after a meal, and the tablets should never be crushed or split. Treatment is continued until disease progression or unacceptable toxicity occurs. Complete blood count (CBC) monitoring is essential during therapy because myelosuppression serves as the dose-limiting toxicity.
Generic availability:
As of 2026, there is no generic version of Inqovi available in the United States. Alternative hypomethylating agents for MDS and CMML include generic intravenous or subcutaneous decitabine, which is much cheaper but requires a 5-day injection or infusion schedule. Generic intravenous or subcutaneous azacitidine is also widely used on a 7-day injection schedule. While oral azacitidine exists, it is approved for AML maintenance rather than MDS, though venetoclax is increasingly used off-label with hypomethylating agents for higher-risk cases.
Warnings:
Inqovi carries warnings for myelosuppression, which can cause severe and prolonged neutropenia, thrombocytopenia, and anemia, making CBC monitoring and transfusion support common. It also presents risks for embryo-fetal toxicity and male reproductive toxicity, meaning men should be advised against fathering children during and for 3 months after therapy. Finally, there are warnings regarding significant drug interactions since cedazuridine is metabolized by cytidine deaminase, though few clinically significant interactions have been documented.
FAQ (Frequently Asked Questions)
How Much Does Inqovi Cost Without Insurance?
Inqovi costs approximately $20,000–$24,000 per 5-day cycle (one cycle every 28 days). Through AffordMyPrescriptions, qualifying patients receive Inqovi at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Inqovi Different From IV Decitabine?
Same active drug (decitabine), different delivery. Inqovi: oral tablet combining decitabine + cedazuridine (which prevents oral decitabine breakdown). Taken at home for 5 days per cycle. Convenient but expensive. IV decitabine (Dacogen, generic): IV infusion typically over 1 hour daily for 5 days (or other schedules). Requires going to infusion center each day during treatment cycle. Generic IV decitabine is dramatically cheaper than Inqovi. Clinical efficacy is comparable. Choice often comes down to convenience vs. cost.
What About IV/SC Azacitidine?
Azacitidine (Vidaza, generic) is another hypomethylating agent for MDS/CMML — given as IV or SC injection for 7 days per 28-day cycle. Some patients respond better to azacitidine than decitabine (or vice versa). The 7-day schedule is longer than decitabine’s 5-day schedule. Generic azacitidine SC is widely available at substantially lower cost than Inqovi. Choice between azacitidine and decitabine is often guided by oncologist preference, patient tolerability, and prior response.
How Long Will I Be On Inqovi?
MDS treatment is typically continued until disease progression or unacceptable toxicity. Responses typically develop over 4–6 cycles (months). Some patients receive Inqovi for years. Treatment is generally not curative for MDS in patients ineligible for allogeneic stem cell transplant — it controls disease, improves blood counts, and reduces transfusion needs.
What Should I Watch For?
Main toxicity is myelosuppression — low white cells (infection risk), low platelets (bleeding risk), and anemia (fatigue, often needing transfusion). CBC is checked frequently. Tell your oncologist promptly about fever, signs of infection, unusual bruising/bleeding, or severe fatigue. Other side effects: nausea (less prominent than IV), constipation/diarrhea, fatigue, mucositis.
Can I Get Inqovi Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to generic IV decitabine (Dacogen, much cheaper but requires daily infusions for 5 days per cycle) or generic SC/IV azacitidine (Vidaza, also cheaper, with 7-day schedule), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Aplastic Anemia and MDS International Foundation, Leukemia & Lymphoma Society, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Inqovi, our team may be able to help you access assistance programs — or guide you to generic IV decitabine or azacitidine. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.